For the genes that we show are involved in prostate cancer prognosis (see further section), CSAD had increased expression in prostate cancer (fold-change = 1.61, FDR < 0.001, Supplementary Table S2), while the expression of SERINC3 did not change according to the criteria used. This evidence concerns the gene CSAD and prostate carcinoma.